Pathogens and Immunity (Jan 2025)
The TB27 Transcriptomic Model for Predicting Mycobacterium tuberculosis Culture Conversion
- Maja Reimann,
- Korkut Avsar,
- Andrew DiNardo,
- Torsten Goldmann,
- Gunar Günther,
- Michael Hoelscher,
- Elmira Ibraim,
- Barbara Kalsdorf,
- Stefan Kaufmann,
- Niklas Köhler,
- Anna Mandalakas,
- Florian Maurer,
- Marius Müller,
- Dörte Nitschkowski,
- Ioana Olaru,
- Cristina Popa,
- Andrea Rachow,
- Thierry Rolling,
- Helmut Salzer,
- Patricia Sanchez-Carballo,
- Maren Schuhmann,
- Dagmar Schaub,
- Victor Spinu,
- Elena Terhalle,
- Markus Unnewehr,
- Nika Zielinski,
- Jan Heyckendorf,
- Christoph Lange
Affiliations
- Maja Reimann
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
- Korkut Avsar
- Asklepios Fachkliniken München-Gauting, Munich, Germany
- Andrew DiNardo
- The Global Tuberculosis Program, Texas Children’s Hospital, Immigrant and Global Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
- Torsten Goldmann
- Division of Histopathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany; German Center for Lung Research (DZL), Airway Research Center North, Borstel, Germany
- Gunar Günther
- Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia; Inselspital Bern, Department of Pulmonology, Bern, Switzerland
- Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP; Immunology, Infection and Pandemic Research, Munich, Germany; Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- Elmira Ibraim
- Institutul de Pneumoftiziologie “Marius Nasta”, MDR-TB Research Department, Bucharest, Romania
- Barbara Kalsdorf
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
- Stefan Kaufmann
- Max Planck Institute for Infection Biology, Berlin, Germany; Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany; Hagler Institute for Advanced Study, Texas A&M University, College Station, TX; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany
- Niklas Köhler
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany; Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Anna Mandalakas
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; The Global Tuberculosis Program, Texas Children’s Hospital, Immigrant and Global Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
- Florian Maurer
- National and WHO Supranational Reference Laboratory for Mycobacteria, Research Center Borstel, Borstel, Germany; Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; new affiliation: Roche Diagnostics, Zurich, Switzerland
- Marius Müller
- Sankt Katharinen-Krankenhaus, Frankfurt, Germany; Infektiologikum, Frankfurt, Germany
- Dörte Nitschkowski
- Division of Histopathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany; German Center for Lung Research (DZL), Airway Research Center North, Borstel, Germany
- Ioana Olaru
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; London School of Hygiene and Tropical Medicine, London, United Kingdom; new affiliation: Medical Microbiology, University of Münster, Germany
- Cristina Popa
- Institutul de Pneumoftiziologie “Marius Nasta”, MDR-TB Research Department, Bucharest, Romania
- Andrea Rachow
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Germany
- Thierry Rolling
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany; new affiliation: Biontech SE, Mainz, Germany
- Helmut Salzer
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine 4-Pneumology, Kepler University Hospital, Linz, Austria; Medical Faculty, Johannes Kepler University Linz, Linz, Austria; Ignaz-Semmelweis-Institute, Interuniversity Institute for Infection Research, Vienna, Austria
- Patricia Sanchez-Carballo
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
- Maren Schuhmann
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
- Dagmar Schaub
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany
- Victor Spinu
- Institutul de Pneumoftiziologie “Marius Nasta”, MDR-TB Research Department, Bucharest, Romania
- Elena Terhalle
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; new affiliation: LungenClinic Großhansdorf, Großhansdorf, Germany
- Markus Unnewehr
- Department of Respiratory Medicine and Infectious Diseases, St. Barbara-Klinik, Hamm, Germany; Department of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany
- Nika Zielinski
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
- Jan Heyckendorf
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; new affiliation: Internal Medicine II, Leibniz LungClinic, University Hospital Schleswig-Holstein (UKSH) Campus Kiel, Germany; new affiliation: Pulmonology and Inflammation Medicine, Christian-Albrechts-University Kiel, Germany
- Christoph Lange
- Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
- DOI
- https://doi.org/10.20411/pai.v10i1.770
- Journal volume & issue
-
Vol. 10,
no. 1
Abstract
Rationale: Treatment monitoring of tuberculosis patients is complicated by a slow growth rate of Mycobacterium tuberculosis. Recently, host RNA signatures have been used to monitor the response to tuberculosis treatment. Objective: Identifying and validating a whole blood-based RNA signature model to predict microbiological treatment responses in patients on tuberculosis therapy. Methods: Using a multi-step machine learning algorithm to identify an RNA-based algorithm to predict the remaining time to culture conversion at flexible time points during anti-tuberculosis therapy. Results: The identification cohort included 149 patients split into a training and a test cohort, to develop a multistep algorithm consisting of 27 genes (TB27) for predicting the remaining time to culture conversion (TCC) at any given time. In the test dataset, predicted TCC and observed TCC achieved a correlation coefficient of r=0.98. An external validation cohort of 34 patients shows a correlation between predicted and observed days to TCC also of r=0.98. Conclusion: We identified and validated a whole blood-based RNA signature (TB27) that demonstrates an excellent agreement between predicted and observed times to M. tuberculosis culture conversion during tuberculosis therapy. TB27 is a potential useful biomarker for anti-tuberculosis drug development and for prediction of treatment responses in clinical practice.
Keywords